IBS vs Celiac Disease: How to Tell the Difference

Celiac disease and irritable bowel syndrome cause the same core symptoms: bloating, abdominal pain, diarrhea, constipation, and fatigue. That overlap is why an estimated 83% of the roughly 3 million Americans with celiac disease remain undiagnosed, many of them told they have IBS. The critical difference is that celiac disease is an autoimmune condition that destroys the lining of the small intestine when exposed to gluten, while IBS involves no structural damage. Telling them apart usually requires one blood test, and the distinction matters because the treatments are completely different.

What is celiac disease, and how is it different from IBS?

Celiac disease is a genetic autoimmune disorder in which ingesting gluten triggers an immune response that attacks the villi of the small intestine. These villi are finger-like projections that absorb nutrients. When they are flattened (a process called villous atrophy), nutrient absorption drops, and symptoms develop. The condition affects approximately 1 in 100 people worldwide according to data published by Rubio-Tapia and colleagues in the American Journal of Gastroenterology (2012).

IBS, by contrast, is a functional gastrointestinal disorder defined by symptom patterns (the Rome IV criteria) without identifiable structural or biochemical abnormalities. There is no tissue damage, no autoimmune process, and no specific blood marker. IBS is a diagnosis of exclusion, which means it should only be assigned after conditions like celiac disease have been ruled out. In practice, that screening step is sometimes skipped.

Where do the symptoms overlap?

The symptom overlap between celiac disease and IBS is extensive. Both conditions commonly present with bloating, abdominal pain or cramping, diarrhea, constipation (yes, celiac can cause constipation), gas, nausea, and fatigue. A clinician looking at symptoms alone cannot reliably distinguish the two. A 2009 study in the American Journal of Gastroenterology by Ford and colleagues found that the prevalence of biopsy-confirmed celiac disease in patients meeting IBS criteria was roughly four times higher than in controls, suggesting that many IBS diagnoses are hiding celiac cases.

What signs point to celiac disease rather than IBS?

While the gut symptoms overlap, celiac disease produces a set of extraintestinal manifestations that IBS does not. These signs result from chronic malabsorption and autoimmune inflammation affecting tissues beyond the intestine. If you have any of the following alongside your GI symptoms, celiac disease should be investigated even if your symptoms were previously attributed to IBS.

How do serological markers separate celiac from IBS?

The most important practical difference between celiac disease and IBS is that celiac produces measurable antibodies in the blood. The tissue transglutaminase IgA (tTG-IgA) test is the recommended first-line screening tool, endorsed by the American College of Gastroenterology and the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. When performed in patients with normal IgA levels who are actively consuming gluten, the tTG-IgA test has sensitivity above 95% and specificity above 95% (Husby et al., 2012).

A total serum IgA level should be measured alongside tTG-IgA because 2 to 3% of celiac patients have selective IgA deficiency, which causes a false negative on IgA-based tests. In those cases, IgG-based tests such as deamidated gliadin peptide (DGP) IgG or tTG-IgG are used instead. IBS, by definition, produces no specific antibodies. If your tTG-IgA is elevated and your total IgA is normal, celiac disease is very likely and an upper endoscopy with duodenal biopsy is the next step.

What about non-celiac gluten sensitivity?

Non-celiac gluten sensitivity (NCGS) occupies a gray area. People with NCGS report symptom improvement on a gluten-free diet but test negative for celiac antibodies and do not have villous atrophy on biopsy. Estimates of prevalence vary widely, from 0.5% to 13% of the population, partly because there is no validated biomarker and diagnosis relies on exclusion of celiac disease and wheat allergy followed by a blinded gluten challenge.

It is important to note that some people labeled with NCGS may actually have undiagnosed celiac disease (particularly seronegative celiac, where antibodies are negative but biopsy is positive), wheat allergy, or FODMAP sensitivity (since wheat is a high-FODMAP food). Before accepting a diagnosis of NCGS, celiac disease should be definitively excluded with both serology and, ideally, biopsy while the patient is still consuming gluten. Once you stop eating gluten, both antibody tests and biopsy findings can normalize, making diagnosis impossible without a gluten challenge.

What is the diagnostic pathway?

If you have IBS symptoms and have never been tested for celiac disease, the diagnostic pathway is straightforward. The most important requirement is that you must be eating gluten regularly (at least the equivalent of two slices of bread per day for a minimum of 6 weeks) before testing. Going gluten-free before testing can produce false-negative results on both blood tests and biopsy.

How does treatment differ between celiac disease and IBS?

Celiac disease has one definitive treatment: a strict, lifelong gluten-free diet. This means eliminating all sources of wheat, barley, and rye, including trace amounts from cross-contamination. When followed correctly, the gluten-free diet allows intestinal villi to regenerate, antibodies to normalize, and symptoms to resolve. Most patients see significant improvement within weeks to months, though complete mucosal healing can take 1 to 2 years in adults (Rubio-Tapia et al., 2010).

IBS treatment, on the other hand, is symptom-based and varies by subtype. It may include dietary modifications (such as a low-FODMAP diet), antispasmodics, neuromodulators, probiotics, behavioral therapy, and management of stress and anxiety. There is no single definitive treatment. The reason the distinction matters so much is that untreated celiac disease carries long-term risks including osteoporosis, infertility, certain lymphomas, and cascading autoimmune conditions. IBS, while significantly impairing quality of life, does not carry these same structural and systemic risks.

Who should be screened for celiac disease?

The American College of Gastroenterology recommends celiac screening for patients with chronic diarrhea, iron deficiency anemia, unexplained weight loss, and other suggestive symptoms. However, given the high rate of undiagnosed cases, many experts argue for broader screening. The following groups should be tested, regardless of whether they have been diagnosed with IBS.